Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.

Aggarwal S1, Vaid A2, Ramesh A3,4, Parikh PM5, Purohit S6, Avasthi B7, Gupta S8, Ranjan S9, Kaushal V10, Salim S11, Singh R12, Minhas S2, Doval D13.

Author information

Abstract

Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. The use of gene expression assays for early stage disease is already common practice. These tests have found a place in risk stratifying the heterogeneous group of stage I-II breast cancers for recurrence, for predicting chemotherapy response, and for predicting breast cancer-related mortality. Most guidelines for hormone receptor (HR)-positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost. Expert oncologist discussed about strategies of gene expression assays and aid in chemotherapy recommendations for treatment of HR + ve EBC and the expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.